- Home
- AMRX
as 09-18-2025 4:00pm EST
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.9B | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.68 - $10.34 | Next Earning Date: | 11-07-2025 |
| Revenue: | $2,852,914,000 | Revenue Growth: | 9.81% |
| Revenue Growth (this year): | 9.56% | Revenue Growth (next year): | 6.27% |
Stock Insider Trading Activity of Amneal Pharmaceuticals Inc. (AMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kiely John | AMRX | Director | Aug 27 '25 | Sell | $9.23 | 32,000 | $295,360.00 | 225,433 | |
| Shah Nikita | AMRX | Executive Vice President | Aug 25 '25 | Sell | $9.50 | 6,340 | $60,230.00 | 146,403 | |
| Shah Nikita | AMRX | Executive Vice President | Aug 22 '25 | Sell | $9.66 | 114,492 | $1,105,992.72 | 146,403 | |
| BOYER ANDREW S | AMRX | Executive Vice President | Aug 20 '25 | Sell | $9.38 | 279,244 | $2,619,308.72 | 152,426 | |
| Konidaris Tasos | AMRX | Executive Vice President & CFO | Aug 15 '25 | Sell | $9.43 | 219,159 | $2,066,669.37 | 122,152 | |
| Konidaris Tasos | AMRX | Executive Vice President & CFO | Aug 14 '25 | Sell | $9.30 | 119,206 | $1,108,615.80 | 122,152 | |
| Shah Nikita | AMRX | Executive Vice President | Aug 14 '25 | Sell | $9.29 | 71,694 | $666,037.26 | 146,403 | |
| Konidaris Tasos | AMRX | Executive Vice President & CFO | Aug 13 '25 | Sell | $9.22 | 161,365 | $1,487,785.30 | 122,152 | |
| Shah Nikita | AMRX | Executive Vice President | Aug 12 '25 | Sell | $9.04 | 50,000 | $452,000.00 | 146,403 | |
| BOYER ANDREW S | AMRX | Executive Vice President | Aug 12 '25 | Sell | $9.05 | 33,436 | $302,595.80 | 152,426 |
Latest Amneal Pharmaceuticals Inc. News
AMRX Breaking Stock News: Dive into AMRX Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
Amneal Pharmaceuticals Receives FDA Approval for Antipsychotic Medicine
GlobeNewswire
14 days ago
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
MT Newswires
a month ago
Amneal Pharmaceuticals Insider Sold Shares Worth $2,619,309, According to a Recent SEC Filing
MT Newswires
3 months ago
Amneal Pharmaceuticals Says Study Evaluating Biosimilar to Xolair For Chronic Hives Achieves Endpoints
GlobeNewswire
3 months ago
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
The Wall Street Journal
3 months ago
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
GlobeNewswire
3 months ago
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
GlobeNewswire
4 months ago
Amneal to Participate at Upcoming Investor Conferences in June
Compare AMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRX Amneal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.